# RMD — ResMed · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** RMD  
**Sources:** 8  
**Published:** 2026-09-27  
**Canonical:** https://app.k3vl4r.com/research/deep-research-rmd-resmed-catalysts-narrative-risks-4982

---

## ResMed (RMD) — Research Snapshot as of 2026-09-27

**Background context (unverified leads, consistent with sources):** NYSE-listed, Healthcare/Medical Instruments & Supplies, market cap ~$32.0–32.1B, fiscal year ends June 30. The on-file earnings date of 2026-10-29 is confirmed by multiple sources [[3]](https://public.com/stocks/rmd/earnings)[[5]](https://www.perplexity.ai/finance/RMD?comparing=RMD%2CCTEC.L%2CALC%2CALGN%2CCAH%2CBAX).

### Recent catalysts (roughly June–September 2026)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-rmd-resmed-catalysts-narrative-risks-4982 (free to sign up)._
